Multicentre evaluation of the in vitro activity of linezolid in the Western Pacific
Journal
Journal of Antimicrobial Chemotherapy
Journal Volume
51
Journal Issue
2
Pages
339-345
Date Issued
2003
Author(s)
Bell J.M.
Turnidge J.D.
Ballow C.H.
Jones R.N.
Turnidge J.
Benn R.
Grayson L.
Faoagali J.
Christiansen K.
Cheng A.
Tsang D.
Kohno S.
Yamaguchi K.
Kahu M.
Woo J.H.
Choi K.W.
Lee K.W.
Yeo M.
Kumarasinghe G.
Liu Y.C.
Leu H.S.
Abstract
Multiresistance to antimicrobial agents is common in staphylococci and pneumococci isolates in the Western Pacific region. The activity of linezolid, a new oxazolidinone, was evaluated against a spectrum of Gram-positive species collected in the region. Eighteen laboratories from six countries in the Western Pacific examined the linezolid susceptibility of 2143 clinical isolates of Staphylococcus aureus, coagulase-negative staphylococci (CoNS) and Enterococcus spp. using broth microdilution or disc diffusion methodology. For Streptococcus pneumoniae (n = 351) and other streptococci (n = 83), Etest (AB Biodisk, Solna, Sweden) strips were used. Results were compared with other common and important antimicrobials. Linezolid-resistant strains were not detected among streptococci or staphylococci, including a significant proportion of S. aureus strains that were multiresistant. Almost all enterococci, including 14 vancomycin-resistant Enterococcus faecium, were linezolid susceptible. A small proportion of enterococci (0.8%) were intermediate to linezolid, and one strain of Enterococcus faecalis had a zone diameter of 20 mm (resistant). The linezolid MIC ranges (MIC(90)) of those strains tested by broth microdilution or Etest were: 1-4 mg/L (2 mg/L) for S. aureus, 0.5-4 mg/L (2 mg/L) for CoNS, 0.5-4 mg/L (2 mg/L) for Enterococcus spp., 0.12-2 mg/L (1 mg/L) for S. pneumoniae and 0.25-2 mg/L (1 mg/L) for Streptococcus spp. There was no difference in linezolid susceptibility between countries or between multiresistant and susceptible strains of each species monitored.
SDGs
Type
journal article